İMREN MUTLU

Dr. İMREN MUTLU

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Turkish Journal of Parasitology
Verified
Journal Article
Closed access
İMİMREN MUTLU
İMREN MUTLU
ÖKÖmer Ruşen Koyuncu
Ömer Ruşen Koyuncu
YCYasemin Cakir
Yasemin Cakir
Hydatid cyst is a zoonotic disease and is an important health problem, especially in developing countries. Hydatic cysts are typically observed in the liver and lungs. Cardiac and brain involvement are rare manifestations. Cardiac hydatic cysts are usually located in the left ventricle. Brain involvement is frequently seen as a primary cerebral cyst and is almost always solitary. However, secondary intracerebral cysts are also seen as a result of cardiac cysts rupturing into the left ventricle spontaneously or iatrogenically, and these are usually multiple. Herein, we report a case that has two rare clinical manifestations of hydatid cysts.

21 February 2025
Verified
Book
Open access
PDF file
ABAnıl Tuğçe Başderici
Anıl Tuğçe Başderici
ZSZekai Emre Sevgilioğlu
Zekai Emre Sevgilioğlu
BABensu Arpat
Bensu Arpat
SASaliha Seda Adanır
Saliha Seda Adanır
İMİMREN MUTLU
İMREN MUTLU
AKAhmet burak Kara
Ahmet burak Kara
Meme ve Axilla Anatomisi Anıl Tuğçe BAŞDERİCİ Meme Kanseri Epidemiyolojisi Zekai Emre SEVGİLİOĞLU Meme Kanseri Taramaları Bensu ARPAT Saliha Seda ADANIR Konvansiyonel Mamografi İmren MUTLU Tomosentez ve Kontrastlı Mamografi Nurcihan YAVUZ SAVAŞ Meme Ultrasonografisi Melis BAYKARA ULUSAN Emine Sevcan ATA Memede Manyetik Rezonans Görüntüleme Büşra SARIAY Memede Girişimsel Radyoloji Tanı Yöntemleri Ceren KARABİBER DEVECİ Benign Meme Lezyonları Suat Kamil SÜT Malign Meme Lezyonları Büşra YAVUZ SARSAM Meme Kanserinde Cerrahi Sonrası Görüntüleme Duygu İmre YETKİN Erkek Meme Hastalıkları Yasin Celal GÜNEŞ Gebelik ve Laktasyon Dönemi Meme Hastalıkları Ahmet Burak KARA Meme Radyolojisinde Yapay Zeka Bekir Sıtkı Said ULUSOY

28 September 2026 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
ESEbru Ozan Sanhal
Ebru Ozan Sanhal
İMİMREN MUTLU
İMREN MUTLU
EBEvrim Sürer Budak
Evrim Sürer Budak
VVVeli Vural
Veli Vural
IZİsMail Zihni
İsMail Zihni
CACumhur Arıcı
Cumhur Arıcı
Accurate assessment of breast cancer response to neoadjuvant chemotherapy (NAC) is important for surgical planning. We compared contrast-enhanced mammography (CEM), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) for predicting breast pathologic complete response (pCR) and assessing residual disease. This retrospective single-center study included 76 patients who underwent all three modalities before and after NAC, followed by surgery. Postoperative histopathology was the reference standard; breast pCR was defined as the absence of residual invasive carcinoma in the breast, irrespective of residual ductal carcinoma in situ. Breast pCR occurred in 28 patients (36.8%). CEM had higher sensitivity than DCE-MRI (89.3% versus 60.7%; p = 0.012) and the highest negative predictive value (92.1%), whereas DCE-MRI had the highest specificity (85.4%) and positive predictive value (70.8%). Accuracy was 79.0%, 76.3%, and 73.7% for CEM, DCE-MRI, and ¹⁸F-FDG PET/CT, respectively, without a significant difference among modalities (p = 0.661). Corresponding areas under the receiver operating characteristic curve were 0.841, 0.844, and 0.769. Among 48 patients with residual invasive disease, intraclass correlation coefficients for CEM and DCE-MRI measurements versus pathology were 0.733 and 0.773, respectively. However, 95% limits of agreement were wide (−34.16 to 25.16 mm and −29.26 to 20.93 mm, respectively), indicating substantial individual-level discrepancies. CEM showed promise for post-NAC breast response assessment in this selected cohort, but the findings do not establish equivalence or interchangeability with DCE-MRI. Individual tumor size estimates require caution, and prospective multicenter validation is warranted.

13 October 2026 in Medicina
Verified
Journal Article
Open access
PDF file
İZİsmail Zihni
İsmail Zihni
BZBurcu Zihni
Burcu Zihni
İMİMREN MUTLU
İMREN MUTLU
DSDemet Sarıdemir
Demet Sarıdemir
MSMehmet Zafer Sabuncuoğlu
Mehmet Zafer Sabuncuoğlu
Background and Objectives: Women who develop breast cancer after a previous cancer of another site have poorer overall survival, yet it is unsettled whether the breast cancer itself is more lethal or whether the deficit reflects competing causes of death in an older, previously treated population. We decomposed this survival deficit by cause of death, defining every endpoint identically across groups. Materials and Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database (17 registries, 2010 to 2020), we studied women with invasive breast cancer as a single primary (n = 473,073), as a second or later primary after a non-breast index cancer (second primary breast cancer, SPBC; n = 26,832), and as a second breast primary (n = 40,252). Cause of death was assigned from the SEER cause-of-death-to-site recode, applied identically across cohorts. Cohorts were compared using cause-specific and Fine–Gray models weighted by an inverse-probability propensity score for age, race and ethnicity, subtype, grade, stage, nodal status, year, marital status, income, and rurality. Results: Breast-cancer mortality was not higher in SPBC than in single-primary disease, and was if anything lower (10-year cumulative incidence 12.0 versus 13.6 percent; weighted cause-specific hazard ratio 1.06). The deficit fell almost entirely to competing, non-breast mortality (35.3 versus 13.5 percent). In a five-way decomposition, cardiovascular disease was not the leading competing cause; non-cancer causes and the index cancer each accounted for more deaths. Once patient factors were balanced, cardiovascular and other non-cancer hazards were near unity (1.05 and 1.07), leaving further cancer death as the main excess. Conclusions: A breast cancer arising after a non-breast cancer is not intrinsically more lethal. Its survival deficit is competing mortality, driven mainly by further cancer death and, to a smaller and largely age-explained degree, by cardiovascular and other non-cancer causes.

21 February 2025
Verified
Book Chapter
Closed access
İMİMREN MUTLU
İMREN MUTLU
Günümüzde, mamografi meme kanseri taramasında etkinliği kanıtlanmış tek yöntem olarak kabul görmektedir. Teknolojinin gelişmesiyle konvansiyonel mamografi yerini çoğunlukla dijital mamografiye bırakmıştır. Mamografi görüntülerinin yüksek kalitede elde edilmesi, tetkikteki bulguların doğru ve anlaşılır tanımlanması ve standart raporlanması klinisyeni doğru yönlendirmede son derecede önemlidir. Kaliteli bir çekimde; doğru pozisyonlanmış, minimum radyasyon dozu ile yüksek kontrast ve uzaysal çözünürlüğü olan, artefaktsız görüntüler elde edilmelidir. Mamografide standart raporlama, farklı merkezlerdeki radyologlar ve klinisyenler arasında dil birliği sağlamada, verilerin kaydedilmesinde ve takibinde ayrıca bulguların malignite riskini belirlemede oldukça önemlidir. Standart mamografi raporunda; kısa bir klinik öykü, inceleme endikasyonu (tarama/ tanısal), mevcut ise önceki tetkikin tarihi ve karşılaştırması, meme parankim yapısı, bulgular belirtilmeli ve sonuç bölümünde bütünsel bir değerlendirme yapılmalı, önerilerde bulunulmalıdır. Mammography is currently accepted as the only evidence-based method for breast cancer screening. The advent of new technology has led to the replacement of conventional mammography with digital mammography. It is of great importance that high-quality mammography images, an accurate and clear description of the findings, and standardised reporting are obtained in order to correctly guide the clinician. In order to obtain an optimal mammogram, it is essential to ensure that the images captured are of the highest quality. To achieve this, it is necessary to correctly position the breast and eliminate artefacts, ensure high contrast and spatial resolution, and minimise the radiation dose used. Standard reporting in mammography is of great importance in facilitating communication between radiologists and clinicians, documentation and follow-up of data, and also assessment of the malignancy risk of findings. In the standard mammography report, a brief clinical history, indication for examination (screening or diagnosis), comparison of previous examinations (if available), description of the breast parenchymal structure, findings and a final evaluation should be provided in the conclusion section, along with recommendations.